Vertex Pharmaceuticals VRTX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 86.2%0.0pp | 86.2%0.0pp | 86.3%+0.2pp | 86.1%+0.1pp | 86%-0.1pp | |
| Operating margin | 38.3%+3.5pp | 34.8%— | —— | —— | —— | |
| Net margin | 35.5%+2.6pp | 32.9%— | —— | —— | —— | |
| Returns | ||||||
| Return on equity | 24.2%+1.7pp | 22.5%— | —— | —— | —— | |
| Return on invested capital | 26.8%+2.5pp | 24.3%-1.4pp | 25.7%-1.3pp | 27%+32.4pp | -5.3%-4.8pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | |
| Liquidity | ||||||
| Current ratio | 3×+0.1× | 2.9×+0.5× | 2.4×-0.2× | 2.5×-0.1× | 2.6×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Net debt / EBITDA | -0.7×0.0× | -0.7×0.0× | -0.7×+0.1× | -0.8×— | —— | |
| Per Share | ||||||
| Book value per share | $75.54+4.4% | $72.35+7.6% | $67.23+1.3% | $66.34+4.4% | $63.57-0.1% | |
| Valuation | ||||||
| Market capitalization | $113.44B-1.4% | $115.03B+14.6% | $100.41B-13.2% | $115.63B-7.1% | $124.5B+20.0% | |
| Price / earnings | 26.1×-2.9× | 29.1×— | —— | —— | —— | |
| Price / sales | 9.3×-0.3× | 9.6×+1.0× | 8.6×-1.6× | 10.1×-1.1× | 11.2×+1.8× | |
| Price / book | 5.9×-0.3× | 6.2×+0.4× | 5.8×-0.9× | 6.7×-0.8× | 7.5×+1.2× | |
| EV / EBITDA | 22.4×-3.1× | 25.5×+3.0× | 22.6×-3.9× | 26.5×— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Vertex Pharmaceuticals's profit margins?
- Vertex Pharmaceuticals (VRTX) runs a 86.2% gross margin and a 38.3% operating margin, with a 35.5% net margin.
- Where do Vertex Pharmaceuticals's ratios come from?
- Every ratio is computed from Vertex Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
